Five Prime Therapeutics’ $173 Million Follow-On Offering

Davis Polk advised the joint-bookrunning managers and representatives of the several underwriters in the offering.

Five Prime Therapeutics, Inc. executed an approximately $173.8 million public offering of common stock. The common stock is listed on the Nasdaq Global Select Market under the symbol “FPRX.”

Cowen and SVB Leerink acted as joint book-running managers for the offering. Wedbush PacGrow acted as co-manager for the offering.

Five Prime is a clinical-stage biotechnology company focused on developing immune modulators and precision therapies to improve the lives of patients with solid tumor cancers. Five Prime’s primary focus is on developing immune-oncology and targeted cancer therapies.

The Davis Polk corporate team included partner Emily Roberts (Picture) and associates Dongbiao Shen and Joseph G. Marano. Partner David R. Bauer and associate Jay Frankel provided intellectual property advice. Partner Mario J. Verdolini and associate Tomislava Dragicevic provided tax advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Tomislava Dragicevic – Davis Polk & Wardwell; Jay Frankel – Davis Polk & Wardwell; Joseph Marano – Davis Polk & Wardwell; Emily Roberts – Davis Polk & Wardwell; Dongbiao Shen – Davis Polk & Wardwell; Mario Verdolini – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Cowen and Company; SVB Leerink LLC; Wedbush PacGrow;

Print Friendly, PDF & Email

Author: Ambrogio Visconti